Evidence map›Paper›PMID 37000222›Full record

ArticleCellular and molecular life sciences : CMLS2023

Functional effects of disease-associated variants reveal that the S1-M1 linker of the NMDA receptor critically controls channel opening.

Lingling Xie, Miranda J McDaniel, Riley E Perszyk, Sukhan Kim, Gerarda Cappuccio, Kevin A Shapiro, Beatriz Muñoz-Cabello, Pedro A Sanchez-Lara, Katheryn Grand, Jing Zhang and 8 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Lingling XieDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Miranda J McDanielDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Riley E PerszykDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Sukhan KimDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Gerarda CappuccioSection of Pediatrics, Department of Translational Medicine, Federico II University, Via Pansini 5, 80131, Naples, Italy.
Kevin A ShapiroDepartment of Neurology, University of California, UCSF Memory and Aging Center, Sandler Neurosciences Center, San Francisco, CA, USA.
Beatriz Muñoz-CabelloDepartment of Pediatrics, University Hospital Virgen del Rocío, Seville, Spain.
Pedro A Sanchez-LaraDivision of Medical Genetics, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, USA.
Katheryn GrandDivision of Medical Genetics, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, USA.
Jing ZhangDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Kelsey A NocillaDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Rehan SheikhDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Lluis ArmengolQuantitative Genomic Medicine Laboratories, SL (qGenomics), Barcelona, Spain.
Roberta RomanoSection of Pediatrics, Department of Translational Medicine, Federico II University, Via Pansini 5, 80131, Naples, Italy.
Tyler Mark PiersonDivision of Pediatric Neurology, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, USA.
Hongjie YuanDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.ORCID https://orcid.org/0000-0002-8127-7145
Scott J MyersDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA.
Stephen F TraynelisDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Road, NE, Atlanta, GA, 30322, USA. strayne@emory.edu.ORCID http://orcid.org/0000-0002-3750-9615
Emory University · USCedars-Sinai Medical Center · USBaylor College of Medicine · USEmory Healthcare · USFederico II University Hospital · ITHospital Universitario Virgen del Rocío · ES

Funding

Glutamate receptors and human neurological diseaseR35NS111619 · NINDS · EMORY UNIVERSITY · PI Stephen F Traynelis · 2019 to 2026
$6.6M
NMDAR Mutations & Neurodevelopmental Disorder: from Mechanism to Targeted TherapyR01HD082373 · NICHD · EMORY UNIVERSITY · PI YUAN, HONGJIE · 2015 to 2025
$3.3M
Use of Bioinformatics and Genetics to Identify a New Class of Drugs for Neurological DiseaseR21AG072142 · NIA · EMORY UNIVERSITY · PI MYERS, SCOTT JAMES · 2021 to 2021
$425k
NIA NIH HHS AG072142NIA NIH HHS R21 AG072142NICHD NIH HHS R01 HD082373NINDS NIH HHS NS111619NINDS NIH HHS R35 NS111619
6 · The paper itself

Abstract

The short pre-M1 helix within the S1-M1 linker (also referred to as the pre-M1 linker) between the agonist-binding domain (ABD, S1) and the M1 transmembrane helix of the NMDA receptor (NMDAR) is devoid of missense variants within the healthy population but is a locus for de novo pathogenic variants associated with neurological disorders. Several de novo variants within this helix have been identified in patients presenting early in life with intellectual disability, developmental delay, and/or epilepsy. In this study, we evaluated functional properties for twenty variants within the pre-M1 linker in GRIN1, GRIN2A, and GRIN2B genes, including six novel missense variants. The effects of pre-M1 variants on agonist potency, sensitivity to endogenous allosteric modulators, response time course, channel open probability, and surface expression were assessed. Our data indicated that virtually all of the variants evaluated altered channel function, and multiple variants had profound functional consequences, which may contribute to the neurological conditions in the patients harboring the variants in this region. These data strongly suggest that the residues within the pre-M1 helix play a key role in channel gating and are highly intolerant to genetic variation.

Indexed as

EpilepsyIntellectual DisabilityReceptors, N-Methyl-D-AspartateHumansMutation, MissenseNerve Tissue ProteinsGRIN1 protein, humanNerve Tissue ProteinsNR2B NMDA receptorReceptors, N-Methyl-D-AspartateChannelopathyGluNGlutamate receptorsGRINPre-M1Translational study

Identifiers

PMID37000222
PMCPMC10641759
OpenAlexW4362520033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.